EBOS GROUP LIMITED — AGM Information 2015

Oct 26, 2015

==> picture [780 x 44] intentionally omitted <==

EBOS Group Ltd

93[rd] Annual Meeting

27 October 2015

Venue: Chateau on the Park, Christchurch, NZ

==> picture [780 x 44] intentionally omitted <==

Important Information

The material contained in this presentation is of general information about the EBOS Group activities current at the date of the presentation. It is information given in summary form and does not purport to be complete. Nothing in this presentation should be construed as a recommendation or forecast by EBOS or an offer to sell or a solicitation to buy or sell shares. It does not take into account the investment objectives, financial situation or needs of a particular investor. These should be considered with or without professional advice when deciding if an investment is appropriate.

==> picture [114 x 43] intentionally omitted <==

2

==> picture [780 x 446] intentionally omitted <==

2015 Annual Meeting 1 Chairman – Mr Rick Christie

EBOS Healthcare facility 3 (Albany, New Zealand)

==> picture [780 x 44] intentionally omitted <==

Agenda

• Welcome

• Introducing members of the Board

• Presentations

• Rick Christie, Chairman

• Patrick Davies, Chief Executive Officer

• Business of meeting

• Conclusion

==> picture [114 x 43] intentionally omitted <==

4

==> picture [780 x 44] intentionally omitted <==

Board of Directors

==> picture [82 x 122] intentionally omitted <==

Rick Christie

Independent Chairman of Directors Joined 2000 Retiring 2015

==> picture [52 x 20] intentionally omitted <==

==> picture [81 x 122] intentionally omitted <==

Mark Waller

Executive Director

Appointed 1987 Chairman Elect

==> picture [82 x 122] intentionally omitted <==

Elizabeth Coutts

Independent Director Joined 2003

==> picture [82 x 122] intentionally omitted <==

==> picture [82 x 122] intentionally omitted <==

==> picture [82 x 122] intentionally omitted <==

Peter Kraus Stuart McGregor Sarah Ottrey Non-executive Director Non-executive Director Independent Director Joined 1993 Joined 2013 Joined 2006

==> picture [81 x 122] intentionally omitted <==

==> picture [82 x 122] intentionally omitted <==

Barry Wallace Peter Williams Non-executive Director Non-executive Director Joined 2001 Joined 2013

==> picture [114 x 43] intentionally omitted <==

5

==> picture [780 x 44] intentionally omitted <==

Strong FY15 Financial Performance

NZ$m	FY15	FY14	Var
Revenue	6,068.1	5,757.2	5.4%
EBITDA	196.7	175.4	12.1%
Net Profit After Tax	105.9	92.1	15.1%
Operating Cash Flow	133.8	114.2	17.2%
EPS - cps	70.8	62.8	12.7%
DPS - cps	47.0	41.0	14.6%
Net Debt : EBITDA	1.6x	1.8x	0.2x
ROCE	13.7%	12.8%	0.9%

Strong Capital Management

• Final dividend of 25.0 cps. Full year dividends of 47.0 cps, up 14.6% on prior year.

• Industry leading cash conversion cycle of 24 days.

• ROCE up 90bps to 13.7%.

==> picture [114 x 43] intentionally omitted <==

6

==> picture [780 x 44] intentionally omitted <==

2015 Annual Meeting 2 CEO – Mr Patrick Davies

A-Frame automatic picking system Symbion Keysborough facility 7 (Victoria, Australia)

==> picture [780 x 44] intentionally omitted <==

EBOS Group Business Overview Our trans-Tasman market channels are delivering strong organic growth

==> picture [764 x 302] intentionally omitted <==

----- Start of picture text -----

HEALTHCARE ANIMAL CARE
Community Pharmacy Institutional Healthcare Contract Logistics Pet Care and Veterinary
Pharmacy Wholesale Product
Pharmacy Services
Pharmacy Retail
Retail
Consumer Products Wholesale
----- End of picture text -----

==> picture [88 x 40] intentionally omitted <==

==> picture [93 x 25] intentionally omitted <==

==> picture [92 x 42] intentionally omitted <==

==> picture [106 x 38] intentionally omitted <==

==> picture [114 x 43] intentionally omitted <==

8

==> picture [780 x 44] intentionally omitted <==

Segment earnings and GOR mix

EBITDA by segment

					Constant FX
NZ$m	FY15	FY14	Var		Var
Healthcare	170.2	153.1	11.2%		13.1%
Animal Care	37.1	29.4	26.1%		27.9%
Corporate	(10.6)	(7.1)	(49.9%)		(47.6%)
Group	196.7	**175.4 **	12.1%		14.2%

• Gross Operating Revenue mix by division has remained stable over the year.

• FY15 Corporate costs reflect the new management structure effective 1 July 2014.

==> picture [114 x 43] intentionally omitted <==

Gross Operating Revenue (GOR) FY15

==> picture [360 x 363] intentionally omitted <==

----- Start of picture text -----

FY15 GOR mix
----- End of picture text -----

9

==> picture [780 x 44] intentionally omitted <==

==> picture [83 x 85] intentionally omitted <==

==> picture [81 x 85] intentionally omitted <==

Healthcare segment overview

Community Pharmacy

• Pharmacy sales in Australia and New Zealand grew and together with productivity improvements generated earnings growth.

Pharmacy Services

==> picture [75 x 74] intentionally omitted <==

==> picture [94 x 25] intentionally omitted <==

• Our investment in GPPW has delivered sales and profit contribution above expectations.

==> picture [126 x 28] intentionally omitted <==

• The 6[th] Community Pharmacy Agreement is effective 1 July 2015. Funding and industry regulation is largely unchanged, including the maintenance of the CSO funding pool for eligible wholesalers.

==> picture [85 x 38] intentionally omitted <==

==> picture [87 x 34] intentionally omitted <==

• Continued emphasis on developing our retail franchise networks and programmes which are delivering positive results for both our pharmacy customers and EBOS, via an increase in the number of member stores.

==> picture [102 x 46] intentionally omitted <==

• Endeavour sales growth was achieved across our brands including Faulding (+29%), Pharmacy Choice (+9.8%) and Chemmart (+6.8%).

==> picture [114 x 43] intentionally omitted <==

10

==> picture [780 x 44] intentionally omitted <==

==> picture [103 x 79] intentionally omitted <==

==> picture [61 x 73] intentionally omitted <==

==> picture [61 x 74] intentionally omitted <==

Healthcare segment overview (continued)

Institutional Healthcare

==> picture [99 x 33] intentionally omitted <==

• EBOS continues to expand its position as a specialised, unique and essential partner across a number of areas of Institutional Healthcare in Australia and New Zealand, primarily in hospitals, aged care and primary care.

==> picture [99 x 30] intentionally omitted <==

==> picture [97 x 30] intentionally omitted <==

• In FY15, Onelink was awarded the NSW Health medical consumables warehousing and distribution contract, reinforcing our position as a proven and trusted partner for Government. Operations are on track to commence in November 2015.

Healthcare Contract Logistics

==> picture [114 x 27] intentionally omitted <==

==> picture [107 x 35] intentionally omitted <==

• Strong performance across both New Zealand and Australia and increased activity with pharmaceutical manufacturers delivered earnings growth.

==> picture [114 x 43] intentionally omitted <==

11

==> picture [780 x 44] intentionally omitted <==

==> picture [78 x 81] intentionally omitted <==

Animal Care segment overview

==> picture [87 x 33] intentionally omitted <==

• The acquisition of BlackHawk has been a successful entry into the premium food market in Australia and compliments our strategy of developing and growing our own brands. There continues to be very strong support for the brand in the pet specialty and retail market and sales continue to grow and track above expectations.

==> picture [92 x 29] intentionally omitted <==

• Masterpet delivered strong revenue growth in FY15 with Vitapet sales increasing by 8.2% (constant FX).

==> picture [58 x 43] intentionally omitted <==

==> picture [88 x 32] intentionally omitted <==

• Lyppard revenue increased 5.7% primarily from growth in major vet groups.

==> picture [86 x 40] intentionally omitted <==

• EBOS’ JV share of Animates net profit increased $0.6m (44%) on LY from like-for-like store sales growth, the opening of three new stores and the acquisition of three Wellington based vet clinics.

==> picture [114 x 43] intentionally omitted <==

12

==> picture [780 x 44] intentionally omitted <==

FY16 Trading Update

• We have made a positive start to the new financial year with our profit performance in the first quarter consistent with the growth rate we delivered in the second half of FY15. This is driven in part by the contribution of the acquisitions made in FY15 which are just now reaching their first anniversary inside our company.

• We are confident of delivering another year of double digit, constant currency profit growth for our shareholders in FY16.

==> picture [114 x 43] intentionally omitted <==

13

==> picture [339 x 156] intentionally omitted <==

==> picture [119 x 178] intentionally omitted <==

==> picture [79 x 154] intentionally omitted <==

==> picture [187 x 126] intentionally omitted <==

2015 Annual Meeting 3 Business of the Meeting

Left: Monash Veterinary Clinic, a customer of Lyppard (Victoria, Australia) 14 Right: Selection of Animal Care products.

==> picture [780 x 44] intentionally omitted <==

Resolution 1

Annual Report and Financial Statements

• To consider and receive the annual report and the financial statements for the year ended 30 June 2015 and the audit report thereon.

==> picture [114 x 43] intentionally omitted <==

15

==> picture [780 x 44] intentionally omitted <==

Resolution 2

Director re-election – Sarah Ottrey

To consider the re-Election of Sarah Ottrey as a Director of the Company.

Sarah Ottrey BCOM

Independent Director

Appointed to the EBOS Group Limited Board in September 2006. Sarah Ottrey is a director of Comvita Limited, Whitestone Cheese Limited and Sarah Ottrey Marketing Limited, and is a member of the Inland Revenue Risk and Assurance Committee. She is a past board member of the Public Trust and the Smiths City Group. Sarah has also held senior marketing management positions with Unilever and Heineken.

==> picture [149 x 222] intentionally omitted <==

==> picture [114 x 43] intentionally omitted <==

16

==> picture [780 x 44] intentionally omitted <==

Resolution 3

Director re-election – Peter Kraus

To consider the re-Election of Peter Kraus as a Director of the Company.

Peter Kraus

MA (HONS), DIP ENG Non-executive Director

Peter Kraus has been a Director of EBOS Group Limited since 1990. He is a member of the Nomination Committee.

He is a director of Whyte Adder No 3 Limited, Herpa Properties Limited, Ecostore Company Limited and Peton Villas Limited.

==> picture [149 x 223] intentionally omitted <==

==> picture [114 x 43] intentionally omitted <==

17

==> picture [780 x 44] intentionally omitted <==

Resolution 4

Director re-election – Stuart McGregor

To consider the re-Election of Stuart McGregor as a Director of the Company.

Stuart McGregor BCOM, LLB, MBA Non-executive Director

Stuart McGregor was appointed to the EBOS Group Limited Board in July 2013. Stuart was educated at Melbourne University and the London School of Business Administration, gaining degrees in Commerce and Law. He has also completed a Masters of Business Administration.

Currently Stuart is Chairman of Donaco International Ltd, an ASX listed company. He is also Chairman of Powerlift Australia Pty Ltd and C B Norwood Pty Ltd and a director of Symbion Pty Ltd.

==> picture [149 x 223] intentionally omitted <==

Over the last 30 years, Stuart’s experience has included Company Secretary of Carlton United Breweries, Managing Director of Cascade Brewery Company Limited in Tasmania and Managing Director of San Miguel Brewery Hong Kong Limited. In the public sector, he served as Chief of Staff to a Minister for Industry and Commerce in the Australian Federal Government and as Chief Executive of the Tasmanian Government’s Economic Development Agency. He was formerly a director of Primelife Limited from 2001 to 2004.

==> picture [114 x 43] intentionally omitted <==

18

==> picture [780 x 44] intentionally omitted <==

Resolution 5 Non-Executive Director remuneration

• To consider the approval, pursuant to NZSX Listing Rule 3.5.1 and ASX Listing Rule 10.17, of an increase of $125,000 in total Non-Executive Director remuneration, from $975,000 per annum to $1,100,000 per annum, with effect from 1 July 2015.

==> picture [114 x 43] intentionally omitted <==

19

==> picture [780 x 44] intentionally omitted <==

Resolution 6

Auditor reappointment and remuneration

• To record the reappointment of Deloitte as Auditors and authorise the Board to determine the auditors remuneration.

==> picture [114 x 43] intentionally omitted <==

20

==> picture [780 x 44] intentionally omitted <==

Other business

• To consider any other business that can be properly brought before the meeting.

==> picture [114 x 43] intentionally omitted <==

21

==> picture [780 x 44] intentionally omitted <==

2015 Annual Meeting

Thank you for attending Please join us for refreshments

www.ebosgroup.com